<h2 dir="ltr"><strong>ALK-NSCLC Overview</strong></h2>
<p dir="ltr">ALK-NSCLC is a distinct molecular lung cancer subtype driven by ALK gene rearrangements, differing biologically and clinically from other forms of NSCLC. This distinction underscores the critical need for molecular testing to identify candidates for targeted treatment.</p>
<h3 dir="ltr"><strong>ALK-NSCLC Epidemiology Segmentation</strong></h3>
<ul>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Total Incident Cases of NSCLC</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Total Eligible Patient Pool for ALK NSCLC</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Total Incident Cases of NSCLC by ALK Biomarker Positive</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Total Treated Cases of ALK NSCLC</p>
</li>
</ul>
<h3 dir="ltr"><strong>ALK-NSCLC Epidemiology&nbsp;</strong></h3>
<ul>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">DelveInsight estimated that the total number of Non-Small Cell Lung Cancer (NSCLC) incident cases in the US in 2024 was nearly 205,000.</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Across the 7MM, there were approximately 25,400 cases of ALK-NSCLC reported in 2024.</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">In the US, the majority of ALK-NSCLC stage-specific cases in 2024 were Stage IV (43.6%), followed by Stage I (29.3%). Stage IIIb represented the lowest proportion at 5.5%.</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Adenocarcinoma was the dominant histology among NSCLC cases in Japan, accounting for the highest occurrence (64%), with squamous cell carcinoma being the next most frequent (26%).</p>
</li>
</ul>
<p dir="ltr">ALK-NSCLC Market</p>
<ul>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">The ALK NSCLC Market Size in the 7MM was approximately USD 2 billion in 2024 and is projected to increase during the forecast period (2025&ndash;2034).</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">The ALK NSCLC Market Size in the US was more than USD 1.2 billion in 2024 and is anticipated to increase due to the launch of emerging therapies.</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">In 2024, Germany dominated the market between EU4 and the UK, generating more than USD 115 million. The UK followed closely with around USD 95 million, while Spain recorded the least.</p>
</li>
</ul>
<h3 dir="ltr"><strong>ALK-NSCLC Market Drivers&nbsp;</strong></h3>
<ul>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">ALK inhibitors provide targeted therapy specifically for tumors with ALK rearrangements, and this specificity is associated with better patient outcomes, including those with brain metastases.</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">The use of genetic testing for ALK mutations, aligned with the movement toward personalized medicine, significantly enhances the selection process for patients who stand to gain the most from ALK inhibitors.</p>
</li>
</ul>
<h3 dir="ltr"><strong>ALK-NSCLC Market Barriers</strong></h3>
<ul>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">While patients often respond well initially to ALK inhibitors, the limited durability of the response underscores the need for continuous research focused on optimizing outcomes through combination therapies.</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">The rapid development of alternative cancer treatments may overshadow ALK-targeted therapies in NSCLC, affecting their market share and usage.</p>
</li>
</ul>
<h3 dir="ltr"><strong>Emerging ALK-NSCLC Drugs</strong></h3>
<ul>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Neladalkib, and others</p>
</li>
</ul>
<h3 dir="ltr"><strong>Key ALK-NSCLC Companies</strong></h3>
<ul>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Roche&nbsp;</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Pfizer</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Takeda</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Betta Pharmaceuticals</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Xcovery&nbsp;</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Chugai Pharmaceutical</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Nuvalent, and others</p>
</li>
</ul>

ALK Non-Small Cell Lung Cancer (ALK+ NSCLC) Market

ALK Non-Small Cell Lung Cancer (ALK+ NSCLC) Symptoms, Treatment, epidemiology, companies, drugs infographic is a short guide to understand the problem and market landscape.